Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-203
- Development stage
- Preclinical
- Lead developer
- University of Illinois
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
miR-203 is a microRNA that functions as a potent tumor suppressor, particularly in glioblastoma (GBM) and other malignancies. It is encoded on chromosome 14q32.33, a region frequently lost in GBM pathogenesis. miR-203 exerts its anti-tumor effects by binding to the 3-untranslated regions (3-UTRs) of several key oncogenic mRNAs, leading to their degradation or translational repression. Validated targets include ROBO1, which regulates cell motility and invasion, and the anti-apoptotic protein BCL-2. Restoration of miR-203 levels through exogenous expression has been shown to inhibit tumor cell migration, invasion, and growth while promoting apoptosis, making it a potential therapeutic candidate for targeted intervention in oncology.
- Other names
- microRNA-203microRNA203microRNA 203hsa-miR-203hsa-miR203hsa-miR 203mir-203mir203mir 203
02
Targets
Platelet-derived growth factor subunit A (PDGFA) mRNAROBO1 (Roundabout guidance receptor 1)BCL-2 (BCL-2 family)Cyclic AMP-responsive element-binding protein 1 mRNA (CREB1 mRNA)
Beyond the preview
Go deeper on miR-203.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-203.